Every 8-K that Cyclerion Therapeutics, Inc. (CYCN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CYCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYCN filings page.
Cyclerion Therapeutics, Inc. (now Korsana Biosciences, Inc., Nasdaq: KRSA) completed its reverse-merger with private Korsana and a 1-for-7 reverse stock split on September 8, 2026, transforming the former shell into a neurology-focused biotech. Following a $380 million private financing completed immediately before closing, the combined company reports approximately $475 million in cash and equivalents, which it states is expected to fund operations into 2029. Korsana securityholders now own about 98.83% of the fully diluted capital stock, while legacy Cyclerion holders own about 1.17%, and total common stock and equivalents are about 55.1 million. Pre‑merger Cyclerion holders also receive non‑transferable contingent value rights tied to 100% of net proceeds from future sales or other dispositions of specified legacy assets. Governance shifts to a six‑member board dominated by Series B preferred investors, who elect four “Preferred Directors” with three votes each, and new leadership appointments include Jonathan Violin, Ph.D. as Chief Executive Officer and President.
Cyclerion Therapeutics, Inc. (CYCN) reported the results of its August 26, 2026 shareholder meeting held in connection with its pending merger with Korsana Biosciences, Inc. Shareholders approved the Nasdaq stock issuance for the merger, an increase in authorized common shares from 400,000,000 to 700,000,000, and a reverse stock split.
The board, with Korsana’s agreement, set the reverse stock split ratio at 1-for-7, which is expected to reduce outstanding common shares from approximately 4.7 million to approximately 0.7 million, while leaving the authorized share count unchanged apart from the approved increase. Fractional shares will be settled in cash based on the Nasdaq closing price on the amendment filing date, and outstanding equity awards and plan share reserves will be adjusted proportionately.
Shareholders also elected six directors, ratified Ernst & Young LLP as auditor for 2026, and approved new 2026 stock incentive and employee stock purchase plans and advisory votes on executive compensation. A proposal to redomesticate to the Cayman Islands was not approved, so the combined company will remain a Massachusetts corporation. Following the reverse split and merger, the combined company’s stock is expected to trade on Nasdaq under the name “Korsana Biosciences, Inc.” and ticker “KRSA” beginning September 9, 2026.
Cyclerion Therapeutics, Inc. (CYCN) reports that its board of directors has set the close of business on September 4, 2026 as the record date for a previously announced distribution of contingent value rights (CVRs) to holders of its common stock and Series A Preferred Stock. The CVR Distribution is tied to Cyclerion’s planned merger with Korsana Biosciences, Inc..
Cyclerion outlines numerous risks that could affect completion and timing of the merger and any potential payments under the CVRs, including failure to obtain shareholder approval, financing, regulatory and Nasdaq listing risks, and potential legal proceedings. Stockholders are directed to review the Form S-4 and related proxy statement/prospectus for detailed information about the merger and CVRs.
Cyclerion Therapeutics agreed to merge with privately held Korsana Biosciences in an all‑stock transaction that effectively hands control to Korsana. Based on the agreed exchange ratio and before the large financing, pre‑merger Korsana stockholders are expected to own approximately 98.5% of the combined company, with pre‑merger Cyclerion shareholders owning about 1.5%.
Concurrently, Korsana investors committed approximately $380 million in a private placement expected to fund operations into 2029 and support development of lead Alzheimer’s candidate KRSA‑028. Cyclerion shareholders will also receive contingent value rights tied to future monetization of legacy assets, while the company plans to rename itself Korsana Biosciences, implement a reverse stock split, create new Series B non‑voting convertible preferred stock and reconstitute the board under Korsana’s leadership.
Cyclerion Therapeutics reported progress on CYC-126, its lead neuropsychiatric therapy for treatment-resistant depression. The company received positive written feedback from the FDA on the design of a Phase 2 proof-of-concept study and the overall regulatory pathway, helping support its planned IND submission.
The planned trial is a randomized, double-blind, two-part study in adults with treatment-resistant depression, using FDA-accepted endpoints such as the MADRS scale. Cyclerion aims to start the Phase 2 study in the second half of 2026, with first patients in Australia and U.S. enrollment beginning in the first half of 2027.
The company also formed a five-member Clinical Advisory Board of leaders in neuropsychiatry, anesthesiology, and clinical development to guide CYC-126 and broader pipeline strategy. The press release reiterates forward-looking risks, including regulatory uncertainty, funding needs, and substantial doubt about the company’s ability to continue as a going concern referenced in prior filings.
Cyclerion Therapeutics entered into a Collaboration and Option Agreement with Medsteer, SAS. Medsteer granted Cyclerion a non-exclusive, worldwide, royalty-free license to use certain Medsteer technology and software to jointly develop an anesthetic delivery system, and also granted Cyclerion an exclusive option to obtain a worldwide, royalty-bearing license to develop or commercialize related products in the defined Company Field.
The option may be exercised at Cyclerion’s discretion during an initial two-year period, which can be extended by an additional two years upon payment of a nominal fee or by mutual agreement. Medsteer is eligible for up to $3.7 million in development, regulatory and sales milestone payments, plus annual and low single-digit percentage royalties on future net sales. Cyclerion and Medsteer will jointly own know-how from the collaboration, and Cyclerion receives a right of first negotiation on transactions involving that know-how. The company also issued a press release and investor presentation updating progress on CYC-126, its lead product candidate.
Cyclerion Therapeutics, Inc. entered into a Patent License Agreement with the Massachusetts Institute of Technology granting Cyclerion an exclusive worldwide license to develop and commercialize products using certain technology for treating neuropsychiatric disorders, such as depression, in humans. Cyclerion will pay MIT a nominal upfront amount and MIT may receive up to $4.4 million in development, regulatory and sales milestone payments, plus tiered royalties in low single-digit percentages on future net sales of licensed products.
Cyclerion will be responsible for development, regulatory approvals and commercialization of licensed products, while MIT will handle filing, prosecution and maintenance of the licensed patent rights in cooperation with Cyclerion. The license term runs until specified patent rights expire, subject to earlier termination under the agreement. Cyclerion also announced its relaunch as a neuropsychiatric company and furnished a press release and investor presentation describing the license and strategic relaunch.